Relmada Therapeutics, Inc. (NASDAQ: RLMD)

$7.43 ▼ -0.06 (-0.80%)

As of May 14, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001553643

Market Cap 642.55 Mn

P/E -6.68

Div. Yield 0.00

Add ratio to table...

About

Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing novel therapeutics for cancer and neurological disorders. The company leverages its drug development expertise and clinical operations capabilities to advance product candidates that address high unmet medical need. Its current pipeline centers on two programs: NDV-01 for non-muscle-invasive bladder cancer and sepranolone for neuropsychiatric conditions. Relmada Therapeutics, Inc. does not generate revenue at present because none of its product...

Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing novel therapeutics for cancer and neurological disorders. The company leverages its drug development expertise and clinical operations capabilities to advance product candidates that address high unmet medical need. Its current pipeline centers on two programs: NDV-01 for non-muscle-invasive bladder cancer and sepranolone for neuropsychiatric conditions.

Relmada Therapeutics, Inc. does not generate revenue at present because none of its product candidates have received regulatory approval for commercial sale. The company anticipates future revenue from the sale of approved products, milestone payments under licensing agreements, and royalties on net sales. Until approval is achieved, the company funds its operations through equity offerings, debt financing, and strategic partnerships.

The company operates through the following segments:

• NDV-01: This segment focuses on the development of a controlled-release intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle-invasive bladder cancer, aiming to provide sustained drug exposure with reduced systemic toxicity.

• Sepranolone: This segment focuses on the development of a neurosteroid epimer of allopregnanolone for potential treatment of Prader-Willi syndrome, Tourette syndrome, essential tremor and other disorders linked to excessive GABAergic activity, seeking to normalize GABA A receptor activity without direct interference with GABA signaling.

Relmada Therapeutics, Inc. positions itself as a specialized biotechnology firm with a strong intellectual property portfolio and experienced management team, competing against larger pharmaceutical companies that possess greater financial and marketing resources. Its competitive advantages include extensive patent coverage for both NDV-01 and sepranolone, a deep understanding of clinical development pathways, and strategic alignments with regulatory agencies such as the FDA to facilitate efficient trial designs.

Relmada Therapeutics, Inc. currently serves no customers because it has no approved products on the market. Upon successful commercialization, the company expects to serve hospitals, urology clinics, oncology centers, neurology practices and patients seeking treatment for bladder cancer or neuropsychiatric disorders.

Investment thesis

Bull case

Relmada’s late‑stage NDV‑01 program delivers a headline‑winning 92% overall response rate in a single‑arm, single‑center phase‑2 study that spans 9 months, a figure that eclipses historical benchmarks for BCG‑unresponsive high‑risk NMIBC patients. The rapid, sustained, intravesical gemcitabine‑docetaxel combination not only meets the efficacy expectations set by the company but does so with a safety profile that is entirely comparable to the established standard, featuring only mild, transient dysuria and hematuria that resolved within a day. Such data give the company a solid scientific foundation to pursue two distinct regulatory pathways, one as a second‑line therapy for BCG‑unresponsive disease and another as an adjuvant option in intermediate‑risk NMIBC, thereby unlocking a combined U.S. patient cohort that ranges from roughly 8,000 to 40,000 individuals per year. The FDA’s favorable alignment on a 505(b)(2) NDA, coupled with the acceptance that no further non‑clinical work is needed, dramatically reduces both the development timeline and the cost of regulatory filings, positioning Relmada to achieve regulatory approval in as early as 2028. Moreover, the pre‑filled, ready‑to‑use formulation eliminates the need for a specialized pharmacy or biocontainment hood, effectively removing a major barrier that has historically limited the adoption of Gemdosi in community urology practices. By offering a five‑minute intravesical installation, Relmada can tap into the approximately 70–80% of NMIBC patients who receive care in community settings, expanding the commercial footprint far beyond the academic centers that have historically managed this therapy. The potential off‑label use of NDV‑01 following the BRIDGE study’s outcomes—where Gemdosi is being compared to BCG in a large, cooperative‑group trial—could further amplify market reach, especially if Gemdosi is shown to be non‑inferior to BCG, thereby creating a new standard of care that sidesteps the persistent supply issues of BCG. Together, these factors underscore a compelling growth trajectory for Relmada that extends beyond the current pipeline and positions the company to capitalize on unmet needs across a sizeable patient population.
Relmada’s 100‑million dollar capital raise, completed in November 2025, has re‑balanced its balance sheet to a cash position that comfortably supports the company’s 2026‑2028 pipeline milestones without immediate financing pressure. This infusion of capital is not only a cushion for the upcoming initiation of the phase‑3 NDV‑01 trials and the proof‑of‑concept Sepranolone study but also provides runway to absorb the inevitable costs associated with scale‑up manufacturing, clinical site activation, and regulatory engagement. The company’s disciplined cost management—evident in the reduction of R&D and general‑administrative expenses in the third quarter—further amplifies its financial resilience, suggesting that Relmada can navigate the typical uncertainties of late‑stage drug development with a solid liquidity foundation. In a market where many small biotechs default once their clinical pipeline stalls, Relmada’s cash runway adds an attractive layer of risk mitigation for investors looking for a mid‑stage asset with credible near‑term milestones. Additionally, the timing of the capital raise aligns with the regulatory milestones achieved, allowing the company to convert the scientific promise of NDV‑01 into tangible commercial momentum without being constrained by funding shortfalls. These elements collectively strengthen the bullish narrative that Relmada is well positioned to transition from a promising early‑stage entity to a potential mid‑stage therapeutic leader.
The introduction of Sepranolone into the therapeutic landscape represents a strategic diversification that extends Relmada’s expertise beyond oncology into neuro‑steroid modulation for compulsive disorders, thereby mitigating the risk of overreliance on a single indication. By targeting Prader‑Willi syndrome, a rare but highly prevalent neuro‑developmental disorder, the company taps into an unmet medical need that currently has no approved pharmacological therapy. Phase‑II data from Tourette’s syndrome patients already demonstrate early signals of efficacy and a tolerability profile that supports progression to a proof‑of‑concept study in the 2026 timeframe. This staged approach—starting with a small‑molecule neuro‑steroid antagonist and leveraging existing pre‑clinical data—allows Relmada to capitalize on the company’s regulatory experience with NDV‑01 while simultaneously exploring a second, potentially lucrative market. Even if the NMIBC program encounters setbacks, the Sepranolone platform provides an alternate revenue stream that could sustain the company through the inevitable vicissitudes of drug development. Thus, the presence of two divergent pipeline assets enhances Relmada’s growth prospects by offering multiple potential entry points into the marketplace.
Relmada’s clinical advisory board, populated with luminaries such as Dr. Yair Lotan and Dr. Max Cates, signals a strong endorsement from the urology community and bolsters confidence in the company’s strategic direction. The inclusion of leaders who have spearheaded landmark trials (e.g., BRIDGE) indicates that Relmada has both clinical insight and credibility to design trials that align with real‑world practice patterns. Such endorsement is crucial for securing enrollment in the upcoming phase‑3 studies and for fostering early adoption among urologists who are key stakeholders in NMIBC treatment decisions. The board’s influence can also facilitate partnerships with high‑volume community centers, accelerating the transition from clinical research to commercial implementation. The depth of clinical expertise embedded in Relmada’s strategy suggests that the company is not only scientifically sound but also strategically positioned to navigate the complexities of clinical trial execution and post‑marketing adoption. Consequently, this robust advisory network enhances the bullish thesis by providing an operational lever that can translate scientific promise into commercial reality.
The company’s strategic emphasis on a “ready‑to‑use” intravesical formulation directly addresses the logistical bottlenecks that have historically constrained the use of Gemdosi. By eliminating the requirement for a specialized pharmacy and reducing the administration time to a few minutes, NDV‑01 can be deployed across a broader spectrum of urology practices, from tertiary academic centers to community hospitals. This operational advantage is especially compelling given that the majority of NMIBC patients are managed in community settings where time and resource constraints are acute. The resulting market expansion not only increases potential patient reach but also improves the cost‑effectiveness profile of the therapy, making it more attractive to payors and providers alike. In a healthcare environment increasingly focused on value‑based care, a product that delivers high efficacy with low implementation burden is positioned for rapid uptake, reinforcing the bullish narrative that Relmada can capture a significant share of the NMIBC market.

Relmada’s late‑stage NDV‑01 program delivers a headline‑winning 92% overall response rate in a single‑arm, single‑center phase‑2 study that spans 9 months, a figure that eclipses historical benchmarks for BCG‑unresponsive high‑risk NMIBC patients. The rapid, sustained, intravesical gemcitabine‑docetaxel combination not only meets the efficacy expectations set by the company but does so with a safety profile that is entirely comparable to the established standard, featuring only mild, transient dysuria and hematuria that resolved within a day. Such data give the company a solid scientific foundation to pursue two distinct regulatory pathways, one as a second‑line therapy for BCG‑unresponsive disease and another as an adjuvant option in intermediate‑risk NMIBC, thereby unlocking a combined U.S. patient cohort that ranges from roughly 8,000 to 40,000 individuals per year. The FDA’s favorable alignment on a 505(b)(2) NDA, coupled with the acceptance that no further non‑clinical work is needed, dramatically reduces both the development timeline and the cost of regulatory filings, positioning Relmada to achieve regulatory approval in as early as 2028. Moreover, the pre‑filled, ready‑to‑use formulation eliminates the need for a specialized pharmacy or biocontainment hood, effectively removing a major barrier that has historically limited the adoption of Gemdosi in community urology practices. By offering a five‑minute intravesical installation, Relmada can tap into the approximately 70–80% of NMIBC patients who receive care in community settings, expanding the commercial footprint far beyond the academic centers that have historically managed this therapy. The potential off‑label use of NDV‑01 following the BRIDGE study’s outcomes—where Gemdosi is being compared to BCG in a large, cooperative‑group trial—could further amplify market reach, especially if Gemdosi is shown to be non‑inferior to BCG, thereby creating a new standard of care that sidesteps the persistent supply issues of BCG. Together, these factors underscore a compelling growth trajectory for Relmada that extends beyond the current pipeline and positions the company to capitalize on unmet needs across a sizeable patient population.
Relmada’s 100‑million dollar capital raise, completed in November 2025, has re‑balanced its balance sheet to a cash position that comfortably supports the company’s 2026‑2028 pipeline milestones without immediate financing pressure. This infusion of capital is not only a cushion for the upcoming initiation of the phase‑3 NDV‑01 trials and the proof‑of‑concept Sepranolone study but also provides runway to absorb the inevitable costs associated with scale‑up manufacturing, clinical site activation, and regulatory engagement. The company’s disciplined cost management—evident in the reduction of R&D and general‑administrative expenses in the third quarter—further amplifies its financial resilience, suggesting that Relmada can navigate the typical uncertainties of late‑stage drug development with a solid liquidity foundation. In a market where many small biotechs default once their clinical pipeline stalls, Relmada’s cash runway adds an attractive layer of risk mitigation for investors looking for a mid‑stage asset with credible near‑term milestones. Additionally, the timing of the capital raise aligns with the regulatory milestones achieved, allowing the company to convert the scientific promise of NDV‑01 into tangible commercial momentum without being constrained by funding shortfalls. These elements collectively strengthen the bullish narrative that Relmada is well positioned to transition from a promising early‑stage entity to a potential mid‑stage therapeutic leader.
The introduction of Sepranolone into the therapeutic landscape represents a strategic diversification that extends Relmada’s expertise beyond oncology into neuro‑steroid modulation for compulsive disorders, thereby mitigating the risk of overreliance on a single indication. By targeting Prader‑Willi syndrome, a rare but highly prevalent neuro‑developmental disorder, the company taps into an unmet medical need that currently has no approved pharmacological therapy. Phase‑II data from Tourette’s syndrome patients already demonstrate early signals of efficacy and a tolerability profile that supports progression to a proof‑of‑concept study in the 2026 timeframe. This staged approach—starting with a small‑molecule neuro‑steroid antagonist and leveraging existing pre‑clinical data—allows Relmada to capitalize on the company’s regulatory experience with NDV‑01 while simultaneously exploring a second, potentially lucrative market. Even if the NMIBC program encounters setbacks, the Sepranolone platform provides an alternate revenue stream that could sustain the company through the inevitable vicissitudes of drug development. Thus, the presence of two divergent pipeline assets enhances Relmada’s growth prospects by offering multiple potential entry points into the marketplace.
Relmada’s clinical advisory board, populated with luminaries such as Dr. Yair Lotan and Dr. Max Cates, signals a strong endorsement from the urology community and bolsters confidence in the company’s strategic direction. The inclusion of leaders who have spearheaded landmark trials (e.g., BRIDGE) indicates that Relmada has both clinical insight and credibility to design trials that align with real‑world practice patterns. Such endorsement is crucial for securing enrollment in the upcoming phase‑3 studies and for fostering early adoption among urologists who are key stakeholders in NMIBC treatment decisions. The board’s influence can also facilitate partnerships with high‑volume community centers, accelerating the transition from clinical research to commercial implementation. The depth of clinical expertise embedded in Relmada’s strategy suggests that the company is not only scientifically sound but also strategically positioned to navigate the complexities of clinical trial execution and post‑marketing adoption. Consequently, this robust advisory network enhances the bullish thesis by providing an operational lever that can translate scientific promise into commercial reality.
The company’s strategic emphasis on a “ready‑to‑use” intravesical formulation directly addresses the logistical bottlenecks that have historically constrained the use of Gemdosi. By eliminating the requirement for a specialized pharmacy and reducing the administration time to a few minutes, NDV‑01 can be deployed across a broader spectrum of urology practices, from tertiary academic centers to community hospitals. This operational advantage is especially compelling given that the majority of NMIBC patients are managed in community settings where time and resource constraints are acute. The resulting market expansion not only increases potential patient reach but also improves the cost‑effectiveness profile of the therapy, making it more attractive to payors and providers alike. In a healthcare environment increasingly focused on value‑based care, a product that delivers high efficacy with low implementation burden is positioned for rapid uptake, reinforcing the bullish narrative that Relmada can capture a significant share of the NMIBC market.

Bear case

The NDA pathway for the BCG‑unresponsive cohort relies on a single‑arm, non‑randomized trial design, a structure that carries inherent regulatory risk given the FDA’s historically cautious stance toward unblinded, single‑arm studies in oncology. While the company cites a high overall response rate, the lack of a contemporaneous control arm raises concerns about confounding variables such as patient selection bias, variability in prior therapies, and differences in disease biology that could inflate perceived efficacy. The FDA’s approval of a single‑arm design may be contingent on stringent endpoints or could be subject to a conditional or accelerated approval that requires additional confirmatory studies, potentially delaying market access and diluting the initial commercial upside. Such regulatory uncertainty could erode investor confidence and impede the company’s ability to secure post‑approval reimbursement, especially if payors perceive the data as less robust than that from randomized controlled trials. Thus, the reliance on a single‑arm design introduces a non‑trivial risk that could undermine the projected growth trajectory for NDV‑01.
The phase‑2 study for NDV‑01 was conducted as a single‑center, ex‑U.S. trial with 25 patients, a sample size that, while suggestive, is statistically limited and may not be representative of the broader, more heterogeneous U.S. NMIBC population. The lack of multi‑center data raises concerns about generalizability, site‑to‑site variability, and the ability to replicate safety and efficacy outcomes in real‑world settings. In oncology, regulators and payors increasingly demand larger, multi‑institutional datasets to confirm the robustness of clinical outcomes, especially when a drug is poised to displace a widely used therapy such as BCG. Until the company can demonstrate consistent results across diverse practice environments, the commercial uptake of NDV‑01 could be slower than anticipated, dampening the anticipated revenue upside and extending the payback period on the substantial capital invested in the program. The modest sample size thus represents a critical bottleneck that could limit the program’s scalability and market acceptance.
While the company’s $100 million capital raise has extended its runway to 2028, the burn rate associated with initiating two concurrent phase‑3 trials (high‑risk BCG‑unresponsive and intermediate‑risk adjuvant) plus the sepranolone program could deplete liquidity sooner than projected if clinical milestones are delayed or if the company needs to engage in additional manufacturing scale‑up or clinical site expansion. The cash position, after accounting for operating expenses, drug development costs, and potential regulatory setbacks, may not provide sufficient cushion for a 3‑year development cycle that includes manufacturing, clinical, and regulatory costs that are inherently uncertain. A liquidity shortfall could force the company to seek additional financing at unfavorable terms or to delay program timelines, thereby extending the time to market and reducing investor returns. Therefore, the financial runway, while superficially adequate, contains embedded risks that could impact the company’s ability to complete the development programs on schedule.
The pricing potential for NDV‑01 remains ambiguous, as the company has refrained from providing concrete pricing guidance and acknowledges that reimbursement will be influenced by the pricing strategy of competing products such as J&J’s Inlexo and Lexo. If the therapy is priced at the higher end of the spectrum, comparable to Inlexo’s ~$700,000 per year, payors may be hesitant to adopt a new drug that offers no clear advantage in efficacy or safety over the current standard. Conversely, if priced lower, the company risks not recouping development costs within a reasonable timeframe. Moreover, the absence of a clear reimbursement strategy could impede market penetration, especially in a payer landscape that is increasingly sensitive to cost‑effectiveness. This uncertainty in the pricing and reimbursement environment creates a significant commercial risk that could limit the therapy’s revenue potential.
The company’s reliance on a pre‑filled, ready‑to‑use formulation to overcome community practice barriers introduces a new manufacturing and supply chain risk. Scaling up production of a sophisticated intravesical delivery system to meet the demands of a nationwide rollout is inherently complex and may encounter unforeseen technical challenges, such as sterility assurance, shelf life, and packaging compliance, that could delay commercial launch. Additionally, the company must navigate the regulatory approval of its manufacturing processes, which could expose it to extended quality control timelines or potential product recalls. Any supply chain disruptions could not only postpone market entry but also erode trust among clinicians and payors, thereby undermining the company’s competitive positioning. These operational uncertainties present a tangible risk that could significantly impact the commercial success of NDV‑01.

The NDA pathway for the BCG‑unresponsive cohort relies on a single‑arm, non‑randomized trial design, a structure that carries inherent regulatory risk given the FDA’s historically cautious stance toward unblinded, single‑arm studies in oncology. While the company cites a high overall response rate, the lack of a contemporaneous control arm raises concerns about confounding variables such as patient selection bias, variability in prior therapies, and differences in disease biology that could inflate perceived efficacy. The FDA’s approval of a single‑arm design may be contingent on stringent endpoints or could be subject to a conditional or accelerated approval that requires additional confirmatory studies, potentially delaying market access and diluting the initial commercial upside. Such regulatory uncertainty could erode investor confidence and impede the company’s ability to secure post‑approval reimbursement, especially if payors perceive the data as less robust than that from randomized controlled trials. Thus, the reliance on a single‑arm design introduces a non‑trivial risk that could undermine the projected growth trajectory for NDV‑01.
The phase‑2 study for NDV‑01 was conducted as a single‑center, ex‑U.S. trial with 25 patients, a sample size that, while suggestive, is statistically limited and may not be representative of the broader, more heterogeneous U.S. NMIBC population. The lack of multi‑center data raises concerns about generalizability, site‑to‑site variability, and the ability to replicate safety and efficacy outcomes in real‑world settings. In oncology, regulators and payors increasingly demand larger, multi‑institutional datasets to confirm the robustness of clinical outcomes, especially when a drug is poised to displace a widely used therapy such as BCG. Until the company can demonstrate consistent results across diverse practice environments, the commercial uptake of NDV‑01 could be slower than anticipated, dampening the anticipated revenue upside and extending the payback period on the substantial capital invested in the program. The modest sample size thus represents a critical bottleneck that could limit the program’s scalability and market acceptance.
While the company’s $100 million capital raise has extended its runway to 2028, the burn rate associated with initiating two concurrent phase‑3 trials (high‑risk BCG‑unresponsive and intermediate‑risk adjuvant) plus the sepranolone program could deplete liquidity sooner than projected if clinical milestones are delayed or if the company needs to engage in additional manufacturing scale‑up or clinical site expansion. The cash position, after accounting for operating expenses, drug development costs, and potential regulatory setbacks, may not provide sufficient cushion for a 3‑year development cycle that includes manufacturing, clinical, and regulatory costs that are inherently uncertain. A liquidity shortfall could force the company to seek additional financing at unfavorable terms or to delay program timelines, thereby extending the time to market and reducing investor returns. Therefore, the financial runway, while superficially adequate, contains embedded risks that could impact the company’s ability to complete the development programs on schedule.
The pricing potential for NDV‑01 remains ambiguous, as the company has refrained from providing concrete pricing guidance and acknowledges that reimbursement will be influenced by the pricing strategy of competing products such as J&J’s Inlexo and Lexo. If the therapy is priced at the higher end of the spectrum, comparable to Inlexo’s ~$700,000 per year, payors may be hesitant to adopt a new drug that offers no clear advantage in efficacy or safety over the current standard. Conversely, if priced lower, the company risks not recouping development costs within a reasonable timeframe. Moreover, the absence of a clear reimbursement strategy could impede market penetration, especially in a payer landscape that is increasingly sensitive to cost‑effectiveness. This uncertainty in the pricing and reimbursement environment creates a significant commercial risk that could limit the therapy’s revenue potential.
The company’s reliance on a pre‑filled, ready‑to‑use formulation to overcome community practice barriers introduces a new manufacturing and supply chain risk. Scaling up production of a sophisticated intravesical delivery system to meet the demands of a nationwide rollout is inherently complex and may encounter unforeseen technical challenges, such as sterility assurance, shelf life, and packaging compliance, that could delay commercial launch. Additionally, the company must navigate the regulatory approval of its manufacturing processes, which could expose it to extended quality control timelines or potential product recalls. Any supply chain disruptions could not only postpone market entry but also erode trust among clinicians and payors, thereby undermining the company’s competitive positioning. These operational uncertainties present a tangible risk that could significantly impact the commercial success of NDV‑01.

Subsegments Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	1,218,282.90 Bn	0.91	-	-
2	ATHE	Alterity Therapeutics Ltd	881,084.00 Bn	-	-	-
3	NBTX	Nanobiotix S.A.	3,028.69 Bn	-96.32	90,432.83	0.11 Bn
4	LEGN	Legend Biotech Corp	2,867.00 Bn	0.00	2,786.90	0.32 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	114.48 Bn	26.49	9.37	-
6	REGN	Regeneron Pharmaceuticals, Inc.	74.20 Bn	16.76	4.97	1.99 Bn
7	EVAX	Evaxion A/S	64.80 Bn	-5,982.48	8,606.93	-
8	ALNY	Alnylam Pharmaceuticals, Inc.	38.98 Bn	77.39	9.09	-

Research Tools